Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot

Enanta Pharmaceuticals reported a Q4 loss of $23.7 million, or 81 cents per share, with revenue of $12.9 million. For the full year, the company had a loss of $68.2 million, or $2.35 per share, on revenue of $63 million, according to the company.

Original reporting
Published Nov 16, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot — source image
Decision brief

The 30-second read

$ENTABearishMed
01

Why it matters

This is a direct earnings datapoint that can influence short-term positioning and subsequent analyst estimate updates, but it does not include guidance, pipeline updates, or balance-sheet details.

02

Market read

Traders can use the reported quarterly loss and revenue to reassess near-term expectations for ENTA, though the lack of guidance limits decision precision.

03

What to watch

The article lacks cash balance, burn rate, pipeline milestones, and any forward guidance, which are typically key for biotech valuation beyond EPS and revenue.

Relevance 7/10Novelty 7/10Timing: reported Monday fiscal Q4 results

Background

The piece is an AP earnings snapshot generated from Zacks data, reporting Enanta’s fiscal Q4 and full-year loss and revenue figures.

Company-level read

Ticker impact

$ENTABearishMedium confidence
Context

Enanta Pharmaceuticals reported fiscal Q4 results, posting a $23.7 million loss and $12.9 million revenue for the quarter.

Expected impact

Likely downward pressure as the market digests the quarterly loss and modest revenue level.

Evidence & confidence

The article discloses the company’s own quarterly EPS loss and revenue, but provides no guidance or segment detail to gauge trajectory beyond the headline figures.

Market effects

Adds another data point for small-cap biotech earnings quality and cash-burn expectations, but no direct read-across catalysts are provided.

Limited, company-specific impact for US biotech investors.

Low, no international regulatory or product developments mentioned.

Counterpoint

Investors may treat the loss as expected for an early-stage biotech and focus on whether revenue trends are stabilizing, rather than the accounting loss.

Key entities

  • Enanta Pharmaceuticals Inc.

    US-listed biotech reporting fiscal Q4 loss and revenue figures.

Related articles

$ENTAMed

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026

ENANTA PHARMACEUTICALS INC (ENTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026 • Completed Enrollment in LOTUS, a Phase 2b Trial of Zelicapavir in Pediatric Patients with Respiratory Syncytial Virus (RSV); Topline Data Expected in 1Q

$ENTAMed

Enanta Pharmaceuticals, Inc. filed a patent infringement action in the Unified Patent Court of the European Union against Pfizer Inc. and certain of its…

ENANTA PHARMACEUTICALS INC (ENTA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, Enanta Pharmaceuticals, Inc. (the “Company”) filed a patent infringement action in the Unified Patent Court (the “UPC”) of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determination of liability

$ENTAMed

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

ENANTA PHARMACEUTICALS INC (ENTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 • Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027 • On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Ri

$ENTAMed

Enanta Was First To File. Pfizer Still Won. The Difference Was One Digit.

The US Federal Circuit affirmed that every claim in Enanta Pharmaceuticals’ patent on a coronavirus protease inhibitor is invalid in Enanta Pharmaceuticals, Inc. v. Pfizer Inc. (Fed. Cir. June 23, 2026). The court said Enanta’s provisional did not disclose the relevant C1 alkyl range, so Pfizer’s April 6, 2021 nirmatrelvir (Paxlovid) presentation was prior art. Paxlovid earned about $19B in 2022.

$ENTAMed

Federal Circuit: Provisional Application Must Support Later Claims

The Federal Circuit in Enanta Pharmaceuticals v. Pfizer (June 23, 2026) affirmed that Pfizer’s Paxlovid-related U.S. Patent No. 11,358,953 cannot claim the provisional application’s July 20, 2020 priority because the provisional lacked written-description support for later claims. The court said changing alkyl range C2 to C1 was not supported, making Pfizer’s nirmatrelvir disclosure prior art and invalidating the asserted claims.